Skip to main content
Premium Trial:

Request an Annual Quote

BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

NEW YORK – BGI Genomics said on Thursday that it has received CE marking for two multiplexed tests for SARS-CoV-2 and influenza A/B produced by its subsidiary BGI PathoGenesis Pharmaceutical Technology.

Both real-time fluorescent RT-PCR tests are for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B from throat swab samples using a single reaction. One test detects the SARS-CoV-2 ORF1ab gene, while the second test detects the virus's ORF1ab and N genes.

As the clinical symptoms of influenza A and influenza B infection and COVID-19 are similar, the new multiplex tests can help rapidly triage testing populations, BGI said.

In March, BGI garnered CE marking for its Real-Time Fluorescent RT-PCR kit for SARS-CoV-2, while its BGI Americas subsidiary received US Food and Drug Administration Emergency Use Authorization for the same test.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.